113.24
price up icon1.96%   2.18
after-market After Hours: 113.30 0.06 +0.05%
loading
Gilead Sciences Inc stock is traded at $113.24, with a volume of 5.23M. It is up +1.96% in the last 24 hours and up +0.21% over the past month. Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$111.06
Open:
$112.43
24h Volume:
5.23M
Relative Volume:
0.58
Market Cap:
$136.94B
Revenue:
$28.73B
Net Income/Loss:
$5.97B
P/E Ratio:
23.84
EPS:
4.75
Net Cash Flow:
$9.84B
1W Performance:
+1.55%
1M Performance:
+0.21%
6M Performance:
+27.04%
1Y Performance:
+67.12%
1-Day Range:
Value
$111.83
$113.67
1-Week Range:
Value
$110.61
$113.67
52-Week Range:
Value
$67.65
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Name
Gilead Sciences Inc
Name
Phone
(650) 574-3000
Name
Address
333 LAKESIDE DR, FOSTER CITY, CA
Name
Employee
17,600
Name
Twitter
@GileadSciences
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
GILD's Discussions on Twitter

Compare GILD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
113.24 136.94B 28.73B 5.97B 9.84B 4.75
Drug Manufacturers - General icon
LLY
Lilly Eli Co
786.92 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
156.28 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
69.69 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
190.62 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
122.94 234.21B 53.22B 12.86B 14.85B 6.39

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Mar-04-25 Reiterated Oppenheimer Outperform
Feb-18-25 Upgrade Deutsche Bank Hold → Buy
Feb-13-25 Upgrade DZ Bank Hold → Buy
Jan-10-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Buy
Nov-08-24 Downgrade Maxim Group Buy → Hold
Oct-21-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-17-24 Initiated Bernstein Outperform
Oct-07-24 Upgrade Wells Fargo Equal Weight → Overweight
Jul-08-24 Upgrade Raymond James Mkt Perform → Outperform
May-01-24 Reiterated Maxim Group Buy
Apr-24-24 Upgrade HSBC Securities Reduce → Hold
Feb-22-24 Downgrade Truist Buy → Hold
Nov-09-23 Initiated Deutsche Bank Hold
Sep-08-23 Upgrade BofA Securities Neutral → Buy
Sep-06-23 Initiated HSBC Securities Reduce
Jul-24-23 Reiterated Barclays Equal Weight
May-16-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-28-23 Resumed Piper Sandler Overweight
Jan-03-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-13-22 Resumed BofA Securities Neutral
Dec-09-22 Downgrade DZ Bank Buy → Hold
Oct-31-22 Upgrade Barclays Underweight → Equal Weight
Oct-28-22 Reiterated BMO Capital Markets Market Perform
Oct-28-22 Reiterated Cowen Outperform
Oct-28-22 Reiterated JP Morgan Overweight
Oct-28-22 Reiterated Jefferies Buy
Oct-28-22 Upgrade Piper Sandler Neutral → Overweight
Oct-28-22 Reiterated RBC Capital Mkts Outperform
Oct-28-22 Upgrade Truist Hold → Buy
Oct-28-22 Reiterated Wells Fargo Equal Weight
Oct-04-22 Upgrade JP Morgan Neutral → Overweight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
May-23-22 Initiated SVB Leerink Mkt Perform
Feb-28-22 Downgrade BMO Capital Markets Outperform → Market Perform
Feb-02-22 Reiterated BMO Capital Markets Outperform
Feb-02-22 Reiterated BofA Securities Neutral
Feb-02-22 Reiterated RBC Capital Mkts Outperform
Feb-02-22 Reiterated Truist Hold
Feb-02-22 Reiterated Wells Fargo Equal Weight
Jan-28-22 Upgrade Argus Hold → Buy
Jan-06-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-09-21 Resumed Wells Fargo Equal Weight
Dec-06-21 Initiated Goldman Neutral
Nov-19-21 Upgrade BMO Capital Markets Market Perform → Outperform
Nov-19-21 Resumed Piper Sandler Neutral
Oct-20-21 Resumed Cowen Outperform
Jul-30-21 Reiterated BMO Capital Markets Market Perform
Jul-30-21 Reiterated RBC Capital Mkts Outperform
Apr-01-21 Upgrade Bernstein Mkt Perform → Outperform
Mar-30-21 Upgrade Redburn Neutral → Buy
Jan-19-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Nov-03-20 Resumed Morgan Stanley Equal-Weight
Oct-28-20 Initiated UBS Neutral
Sep-30-20 Resumed Jefferies Buy
Sep-15-20 Upgrade Maxim Group Hold → Buy
Jul-31-20 Reiterated Credit Suisse Neutral
Jul-31-20 Reiterated Morgan Stanley Equal-Weight
Jul-31-20 Reiterated Piper Sandler Overweight
Jul-31-20 Reiterated RBC Capital Mkts Outperform
Jul-31-20 Reiterated SunTrust Hold
Jul-31-20 Reiterated Wells Fargo Equal Weight
Jul-20-20 Upgrade Credit Suisse Underperform → Neutral
Jun-03-20 Upgrade SVB Leerink Mkt Perform → Outperform
May-26-20 Upgrade SunTrust Sell → Hold
May-01-20 Downgrade JP Morgan Overweight → Neutral
May-01-20 Downgrade Raymond James Outperform → Mkt Perform
May-01-20 Downgrade SunTrust Hold → Sell
Apr-27-20 Downgrade UBS Buy → Neutral
Apr-20-20 Downgrade BMO Capital Markets Outperform → Market Perform
Apr-20-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-17-20 Downgrade CFRA Hold → Sell
View All

Gilead Sciences Inc Stock (GILD) Latest News

pulisher
Jun 19, 2025

Gilead Sciences Lands First FDA Approval of a Twice-a-Year HIV PrEP Drug - MedCity News

Jun 19, 2025
pulisher
Jun 18, 2025

US FDA approves Gilead's twice-yearly injection for HIV prevention - Deccan Herald

Jun 18, 2025
pulisher
Jun 18, 2025

US approves Gilead’s twice-yearly injection to prevent HIV - The Malaysian Reserve

Jun 18, 2025
pulisher
Jun 18, 2025

US approves Gilead's twice-yearly injection to prevent HIV - El Paso Inc.

Jun 18, 2025
pulisher
Jun 18, 2025

The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it - Shelton Herald

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences facility video - KTIV

Jun 18, 2025
pulisher
Jun 18, 2025

HIV prevention drug lenacapavir approved by FDA as twice-yearly injection - CBS News

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves Gilead's twice-yearly HIV prevention shot - FirstWord Pharma

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Wins Historic Approval for Twice-Yearly HIV Drug - BioSpace

Jun 18, 2025
pulisher
Jun 18, 2025

HIV advance: Twice-yearly shot to prevent infection - NZ Herald

Jun 18, 2025
pulisher
Jun 18, 2025

Cautious Optimism for Gilead Sciences Amid Yeztugo’s Market Challenges - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's twice-yearly PrEP drug is cleared by FDA - pharmaphorum

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves twice-yearly shot of Gilead drug for HIV prevention - BioPharma Dive

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It? - Investor's Business Daily

Jun 18, 2025
pulisher
Jun 18, 2025

US Approves Gilead's Twice-yearly Injection To Prevent HIV - Barron's

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approves Gilead’s Twice-Yearly Injection for HIV Prevention - The Well News

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves 6-month HIV prevention shot - The Hill

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's (GILD) HIV Treatment Yeztugo Gains FDA Approval, Market Potential Expands | GILD Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approval Boosts Gilead's (GILD) Prospects in HIV Prevention | GILD Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences stock steady as FDA approves twice-yearly HIV prevention - Investing.com UK

Jun 18, 2025
pulisher
Jun 18, 2025

Mizuho says Gilead Yeztugo label looks clean - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences (GILD) Gains FDA Nod for HIV Prevention Drug - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time. - Barron's

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences’ Yeztugo Approval and Market Expansion Drive Buy Rating - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves powerful HIV prevention drug: What to know about Yeztugo - NBC News

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves the world’s only twice-a-year shot to prevent HIV - mypanhandle.com

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention - ContagionLive

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead’s twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead - Proactive financial news

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences' HIV Prevention Drug Yeztugo Receives FDA Approval - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead (GILD) Gains FDA Approval for Unique HIV Prevention Drug Yeztugo | GILD Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead’s Twice-a-Year HIV Prevention Shot Wins US FDA Approval - Bloomberg.com

Jun 18, 2025
pulisher
Jun 18, 2025

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection - marketscreener.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's (GILD) Lenacapavir Advances as HIV Prevention Treatment - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead (GILD) Gains FDA Approval for HIV Prevention Injection | - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead’s twice-yearly HIV prevention shot gets FDA approval - Investing.com Australia

Jun 18, 2025
pulisher
Jun 18, 2025

US FDA approves Gilead’s twice-yearly injection for HIV prevention By Reuters - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead’s twice-yearly HIV prevention shot gets FDA approval By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead stock gains on FDA nod for HIV PrEP drug (GILD:NASDAQ) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option - CNBC

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access? - STAT

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Says Gilead's Yeztugo Receives FDA Approval For HIV Prevention - marketscreener.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award - CSRwire

Jun 18, 2025
pulisher
Jun 18, 2025

Buy, Sell, Or Hold GILD Stock? - Trefis

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jun 18, 2025
pulisher
Jun 18, 2025

Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's HIV drug could end epidemic, but the company has a dark side - Fast Company

Jun 18, 2025
pulisher
Jun 17, 2025

Insider Sell: Andrew Dickinson Sells 2,500 Shares of Gilead Sciences Inc (GILD) - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: ReportGilead Sciences (NASDAQ:GILD) - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern - Insider Monkey

Jun 17, 2025
pulisher
Jun 16, 2025

Levi & Korsinsky Investigates Gilead Sciences, Inc. (GILD) Over Possible Securities Fraud - ACCESS Newswire

Jun 16, 2025

Gilead Sciences Inc Stock (GILD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general PFE
$25.56
price down icon 0.23%
drug_manufacturers_general SNY
$48.83
price up icon 1.35%
$296.52
price down icon 0.16%
drug_manufacturers_general MRK
$83.71
price up icon 2.88%
drug_manufacturers_general NVS
$122.94
price up icon 1.04%
Cap:     |  Volume (24h):